Europe (WHO region) vs Papua New Guinea: Hepatitis B surface antigen (HBsAg) prevalence (%)
Europe (WHO region)
0.1%
in 2024
Papua New Guinea
2.5%
in 2024
Europe (WHO region) rank
10th
Papua New Guinea rank
10th
Hepatitis B surface antigen (HBsAg) prevalence (%) over time
- Europe (WHO region)
- Papua New Guinea
How they compare
Papua New Guinea currently reports 2.5% against 0.1% in Europe (WHO region), a difference of 2.4%.
That makes Papua New Guinea's figure about 25.0 times Europe (WHO region)'s.
Across all 10 years both countries report, Papua New Guinea has been ahead every year.
Europe (WHO region) ranks 10th and Papua New Guinea ranks 10th of 13 groups.
Papua New Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 2.0% | 1.9% | Papua New Guinea |
| 2020s | 0.1% | 2.4% | 2.3% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Europe (WHO region) or Papua New Guinea?
- Papua New Guinea, at 2.5% against 0.1% in Europe (WHO region) as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Europe (WHO region) and Papua New Guinea?
- 2.4%, with Papua New Guinea ahead.
- How many years of comparable data are there for Europe (WHO region) and Papua New Guinea?
- 10 years are reported by both, from 2015 to 2024.
- How do Europe (WHO region) and Papua New Guinea rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Europe (WHO region) ranks 10th and Papua New Guinea ranks 10th of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.